GlassScriptPhysician profile
Gregory L Champion
NPI 1497798995
$12,812.77
in general payments reported to CMS, 2019-2025
40 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $694 · 2021: $1,356 · 2022: $2,036 · 2023: $2,576 · 2024: $2,862 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,763 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,763.39 |
| Education | $195.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,865.31 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,179.30 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Janssen Biotech, INC. | $1,859.90 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,205.54 | 2019-2025 | Entyvio |
| Pfizer INC. | $924.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $426.18 | 2019-2024 | Dificid |
| Celgene Corporation | $418.26 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $372.88 | 2019-2024 | Linzess |
| Genzyme Corporation | $308.68 | 2022-2025 | |
| Madrigal Pharmaceuticals | $267.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $229.82 | 2022-2024 | Gimoti |
| Gilead Sciences, INC. | $216.91 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $188.00 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $176.25 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $151.37 | 2024-2025 | Omvoh |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Champion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.